SBIR-STTR Award

Screening and analysis of mammalian mutational risk
Profile last edited on: 1/8/2015

Program
SBIR
Agency
NIH | NIEHS
Total Award Amount
$741,039
Award Phase
2
Principal Investigator
Yu Yongjia
Activity Indicator

Company Information

Laboratories for Genetic Services Inc

7400 Fannin Street
Houston, TX 77054
   (713) 798-9500
   N/A
   N/A
Multiple Locations:   
Congressional District:   09
County:   Harris

Phase I

Phase I year
1989
Phase I Amount
$44,153
A long-term objective of Laboratories for Genetic Services, Inc., is to provide an accurate, rapid, simple, and cost-effective methodology for mammalian (rodent and human) mutagenic testing, detection, and classification for the prevention of genetic disease and cancer. GENE*DETEQ will(1) identify existing and new mutagens,(2) improve the system of mutagenic classification,(3) provide a system for the identification of a particular mutagen based on its unique mutagenic sequence characteristics.In Phase I, the molecular methods of ribonuclease A cleavage of RNA:RNA hybrids for mammalian mutation detection and analysis were established. In Phase II, new methods based on polymerase chain reaction and automated direct DNA sequencing will be developed to study molecular specificity of mutagens and suspected mutagenic agents in the environment. The use of GENE*DETEQ will provide(1) a simple means for precise identification of DNA sequence changes involved in mutation,(2) a qualitative method for determining mutagenic mechanisms.

Anticipated Results:
When fully developed and validated, GENE*DETEQ will be used as a reliable mammalian mutational assay by industry and government for the protection of humans and the environment from potentially mutagenic hazards in chemicals, foods, drugs, and radiation. The commercial value of using GENE*DETEQ for the testing and evaluation of product safety and environmental health will be several million dollars annually.National Institute Of Environmental Health Sciences (NIEHS)

Phase II

Phase II year
1990 (last award dollars: 1992)
Phase II Amount
$696,886
A long term objective of Laboratories for Genetic Services, Inc. (LGS) is to provide an accurate, rapid, simple and cost-effective methodology for mammalian (rodent and human) mutagenic testing, detection and classification for the prevention of genetic disease and cancer. GENE*DETEQ will (i) identify existing and new mutagens, (ii) improve the system of mutagenic classification and (iii) provide a system for the identification of a particular mutagen based on its unique mutagenic sequence characteristics. In GENE*DETEQ Phase I, LGS established the molecular methods of ribonuclease A cleavage of RNA:RNA hybrids for mammalian mutation detection and analysis. In GENE*DETEQ Phase II new methods based on polymerase chain reaction and automated direct DNA sequencing will be developed to study molecular specificity of mutagens and suspected mutagenic agents in the environment. The use of GENE*DETEQ will provide (i) a simple means for precise identification of DNA sequence changes involved in mutation and (ii) a qualitative method for determining mutagenic mechanisms. Industria and Governmental application of GENE*DETEQ will provide for public protection arising from exposure to environmental mutagens